
    
      Primary efficacy analysis will be performed on the ITT population. Secondary efficacy
      analysis will be performed on both ITT and PP sets. Results will be summarised by treatment
      and age (overall, 18-35, 36-49, 50-74 and 75-85 years old) and provided in individual data
      listings.

      Safety analysis will be performed on the safety set (ITT population). Safety data of all
      patients exposed will be summarised by treatment and age (overall, 18-35, 36-49, 50-74 and
      75-85 years old).

      Acceptability analysis will be performed on the ITT population. Acceptability data of all
      patients will be summarised by treatment and age (overall, 18-35, 36-49, 50-74 and 75-85
      years old).
    
  